Open Access Articles- Top Results for Loxapine


Systematic (IUPAC) name
Clinical data
Trade names Loxapac, Loxitane, Adasuve
AHFS/ monograph
MedlinePlus a682311
Licence data EMA:Link, US Daily Med:link
  • US: C (Risk not ruled out)
Inhalation, oral
Pharmacokinetic data
Protein binding 96.8%[1]
Metabolism Liver, extensive; active metabolites include amoxapine and 8-hydroxyloxapine. Inhibits P-glycoprotein and is a substrate of CYP1A2, CYP3A4 and CYP2D6[1]
Half-life Oral, 4 hours; Inhalation, 7.61 hours [1]
Excretion Majority are excreted within 24 hours. Main route through urine(conjugated metabolites); Small amounts through the faeces(unconjugated metabolites)
1977-10-2 7pxY
PubChem CID 3964
IUPHAR ligand 205
DrugBank DB00408 7pxN
ChemSpider 3827 7pxY
UNII LER583670J 7pxY
KEGG D02340 7pxY
ChEBI CHEBI:50841 7pxN
Chemical data
Formula C18H18ClN3O
327.808 g/mol
Physical data
Melting point Script error: No such module "convert".
 14pxN (what is this?)  (verify)

Loxapine is a typical antipsychotic medication, used primarily in the treatment of schizophrenia. Trade names for loxapine taken by mouth include Loxapac and Loxitane; the inhalable form is approved as Adasuve. The drug is a member of the dibenzoxazepine class and structurally related to clozapine (which belongs to the chemically akin class of dibenzodiazepines). Several researchers have argued that loxapine may behave as an atypical antipsychotic.[2]

Loxapine may be metabolized by N-demethylation to amoxapine, a tetracyclic antidepressant.[3]

Therapeutic uses and dosages

The typical starting dosage is 10 mg twice daily; usual dose range 30–50 mg twice daily; maximum recommended dosage is 250 mg per day. The US Food and Drug Administration (FDA) has approved loxapine inhalation powder 10 mg (Adasuve, Alexza Pharmaceuticals) for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults.[4]

A brief review of loxapine[5] found no conclusive evidence that it was particularly effective in patients with paranoid schizophrenia. A subsequent systematic review considered that the limited evidence did not indicate a clear difference in its effects from other antipsychotics.[6]

Loxapine was one of five antipsychotics used in a study on the structure of neurons in parts of the brain thought to be involved in schizophrenia. Only loxapine was linked to the development of new connections between neurons.[7]


This drug is unrelated to the habit-forming benzodiazepines, and misuse is rare.[8] The risks and side effect profile are comparable to other antipsychotics.

Side effects

Further information: Typical antipsychotic

Note: Percentages given after possible adverse effects refer to the incidence of said adverse effects, according to DrugPoint.[1]

Common side effects of loxapine (≥1% incidence) when inhaled include
  • Taste sense altered (14%)
  • Sedated (12%)
  • Pharyngitis (3%)
Common side effects of orally-administered loxapine include
  • Constipation
  • Dry mouth
  • Akathisia
  • Dizziness
  • Intense Sleeping (Highest Percentage)
  • Blurred Speech
  • Extrapyramidal disease (dose-dependent. At lower dosages its propensity for causing extrapyramidal side effects appears to be similar to that of atypical antipsychotics[9]
  • Blurred vision
  • Urinary retention
  • Somnolence (which appears to be moderate in severity compared to other antipsychotic drugs[10])
  • Dyspnoea
  • Nasal congestion
Rare side effects include


The data in the following table was obtained from the PDSP Ki database and they are for binding towards human cloned proteins (receptor and transporter) unless otherwise specified.[11]

Molecular target Binding affinity (Ki [nM]) for loxapine Binding affinity (Ki [nM]) for amoxapine
5-HT1A 2456 -
5-HT1B 388 -
5-HT1D 3468 -
5-HT1E 1399 -
5-HT2A 6.63 0.5
5-HT2C 13.3 2 (Cloned rat receptor protein)
5-HT3 190 -
5-HT5A 776 -
5-HT6 31.0 50
5-HT7 87.6 40.2 (Rat, Cloned)
α1A 31 -
α1B 53 -
α2A 150.9 -
α2B 107.8 -
α2C 80.0 -
β1 >10000 -
β1 >10000 -
M1 119.5 -
M2 445 -
M3 211.3 -
M4 1266 -
M5 166 -
D1 54 -
D2 11 20.8
D3 19.33 21
D4 8.4 21
D5 75 -
H1 4.9 -
H2 208 -
H4 5048 -
SERT >10000 58
NET 5698 16
DAT >10000 58



  1. 1.0 1.1 1.2 1.3 1.4 1.5 1.6 Truven Health Analytics, Inc. DrugPoint® System (Internet) [cited 2013 Sep 21]. Greenwood Village, CO: Thomsen Healthcare; 2013.
  2. Glazer WM (1999). "Does loxapine have "atypical" properties? Clinical evidence". The Journal of Clinical Psychiatry 60 (Suppl 10): 42–6. PMID 10340686. 
  3. Cheung SW, Tang SW, Remington G (March 1991). "Simultaneous quantitation of loxapine, amoxapine and their 7- and 8-hydroxy metabolites in plasma by high-performance liquid chromatography". Journal of Chromatography 564 (1): 213–21. PMID 1860915. doi:10.1016/0378-4347(91)80083-O. 
  4. Harrison, Pam: Inhalant Approved for Agitation in Bipolar I, Schizophrenia. Medscape. Dec 24, 2012.
  5. "Clozapine and loxapine for schizophrenia". Drug and Therapeutics Bulletin 29 (11): 41–2. May 1991. PMID 1747161. 
  6. Chakrabarti A, Bagnall A, Chue P et al. (2007). Chakrabarti, Abhijit, ed. "Loxapine for schizophrenia". Cochrane Database of Systematic Reviews (Online) (4): CD001943. PMID 17943763. doi:10.1002/14651858.CD001943.pub2. 
  7. Brennand, Kristen; Anthony Simone, Jessica Jou, Chelsea Gelboin-Burkhart, Ngoc Tran, Sarah Sangar, Yan Li, Yangling Mu, Gong Chen, Diana Yu, Shane McCarthy, Jonathan Sebat & Fred H. Gage (13 April 2011). "Modelling schizophrenia using human induced pluripotent stem cells". Nature 473 (7346): 221–5. PMC 3392969. PMID 21490598. doi:10.1038/nature09915. 
  8. Sperry L, Hudson B, Chan CH (March 1984). "Loxapine abuse". The New England Journal of Medicine 310 (9): 598. PMID 6694719. doi:10.1056/NEJM198403013100920. 
  9. Nordstrom K. Inhaled loxapine for rapid treatment of agitation in schizophrenia and bipolar disorder: an update. Neuropsychiatry [Internet]. 2012 Jun [cited 2013 Sep 21];2(3):253–60. Available from:
  10. Taylor D, Paton C, Kapur S, Taylor D, South London and Maudsley NHS Trust. The Maudsley prescribing guidelines in psychiatry [Internet]. Chichester, West Sussex: John Wiley & Sons; 2012 [cited 2013 Sep 21]. Available from:
  11. National Institute of Mental Health. PDSD Ki Database (Internet) [cited 2013 Aug 3]. Chapel Hill (NC): University of North Carolina. 1998-2013. Available from:
  12. Schmutz, J.; Künzle, F.; Hunziker, F.; Gauch, R. (1967). "Über in 11-Stellung amino-substituierte Dibenzo[b,f]-1, 4-thiazepine und -oxazepine. 9. Mitteilung über siebengliedrige Heterocyclen". Helvetica Chimica Acta 50: 245. doi:10.1002/hlca.19670500131.  edit

External links

Template:Navbox with collapsible sections